Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung Cancer - a podcast by PVI, PeerView Institute for Medical Education
from 2020-08-19T18:00
Go online to PeerView.com/APK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have firmly established their role as a major component of the lung cancer treatment arsenal. In the first-line setting of advanced NSCLC, there are a number of monotherapy and combinatorial strategies (such as combining immune checkpoint inhibitors with chemotherapy regimens, antiangiogenic therapies, and other immunotherapies with non-redundant mechanisms of action) that have FDA-approved indications and are recommended in various best practice guidelines. In addition, increasing evidence is supporting the use of immunotherapies in locally advanced and earlier disease settings, including as neoadjuvant and adjuvant treatments in patients with resectable NSCLC. More recently, the immunotherapy era arrived in SCLC, with new approvals in different settings. Other novel therapies have also improved patient outcomes in extensive-stage SCLC, such as transcription inhibitors. This educational on-demand activity based on a recent live webcast features a panel of leading experts who engage in candid conversations about the modern management of lung cancer. In addition to reviewing the essential established and new clinical data and approvals/indications of immunotherapies, combinations, and other novel treatment options for NSCLC and SCLC, they discuss insightful registry and survey findings regarding patient perspectives, experiences, and needs, as well as the increasing importance of individualizing treatment selection and patient engagement in care planning. Evidence reviews are framed with case scenarios to illustrate the nuances of clinical decision-making in the context of a complex treatment landscape and a variety of tumor-, patient-, and treatment-related factors that should inform these decisions. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of approved and investigational immunotherapies, combinations, and other novel therapies in lung cancer, including NSCLC and SCLC, Evaluate the roles of predictive biomarkers (PD-L1, TMB) and other relevant disease-, and treatment-related factors as well as patient needs and preferences that should be taken into consideration as part of individualized treatment planning and selection for patients with lung cancer, Describe key new research directions and clinical trials evaluating cancer immunotherapy biomarkers, rational immunotherapy-based treatment strategies, and other emerging therapies in different subtypes and settings of NSCLC and SCLC to refine, expand, and maximize the use of optimal therapies throughout the disease continuum, Educate patients with lung cancer and their caregivers about cancer immunotherapies and other treatment options to help them become well-informed participants in their care, Implement individualized, evidence-based, patient-centric treatment plans for patients with lung cancer.
Further episodes of PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Further podcasts by PVI, PeerView Institute for Medical Education